AMCAL NICOTINE LOZENGES 2mg nicotine (as nicotine polacrilex) lozenge blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

nicotine polacrilex, Quantity: 13.33 mg (Equivalent: nicotine, Qty 2 mg)

Disponível em:

Orion Laboratories Pty Ltd T/A Perrigo Australia

DCI (Denominação Comum Internacional):

Nicotine polacrilex

Forma farmacêutica:

Tablet, uncoated

Composição:

Excipient Ingredients: mannitol; sodium carbonate; xanthan gum; potassium bicarbonate; sodium alginate; magnesium stearate; aspartame; Flavour

Via de administração:

Buccal

Unidades em pacote:

120, 108, 96, 156, 36, 144, 132, 168, 72

Tipo de prescrição:

Not Scheduled after consideration by Committee

Indicações terapêuticas:

Relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. Nicotine Lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. If possible, when stopping smoking, should be used in conjunction with behavioural support program.

Resumo do produto:

Visual Identification: Cream/white embossed biconvex round tablet with an odour of peppermint. Embossed with 'L344' on one face.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2013-08-15